Cantitate/Preț
Produs
Total produse
Vezi coșul
Targeting the DNA Damage Response for Cancer Therapy de Timothy A. Yap

Targeting the DNA Damage Response for Cancer Therapy: Cancer Treatment and Research, cartea 186

Editat de Timothy A. Yap, Geoffrey I. Shapiro
en Limba Engleză Hardback – 18 noi 2023
This book discusses the latest developments in Poly (ADP-ribose) polymerase (PARP) inhibitor drug development. It focuses on the translational and clinical development of the latest drugs, as well as the evidence for regulatory approval of PARP inhibitors in multiple different molecular subtypes and tumor indications. The most-up-to-date information on basic scientific research on DNA repair pathways and the DNA Damage Response (DDR) is also covered. Every chapter contains insight into the preclinical, translational along with clinical aspects of a specific DDR inhibitor with key and expert opinion points reinforcing the most important concepts detailed to enable the reader to develop a deep understanding of the topic.

Targeting the DNA Damage Response for Cancer Therapy comprehensively reviews the application of PARP and other DDR inhibitors across oncology disciplines. Therefore, it is a valuable resource for all medical professionals and researchers who use or who are researching the use of these inhibitors on a day-to-day basis.

Citește tot Restrânge

Din seria Cancer Treatment and Research

  • 5% T-Cell and NK-Cell Lymphomas: From Biology to Novel Therapies
    Preț: 108442 lei
  • 5% HIV/AIDS-Associated Viral Oncogenesis
    Preț: 71408 lei
  • 5% Tumor Microenvironment
    Preț: 77432 lei
  • 5% Cancer Immunotherapies: Solid Tumors and Hematologic Malignancies
    Preț: 102041 lei
  • 5% Cancer Drug Safety and Public Health Policy: A Changing Landscape
    Preț: 101521 lei
  • 5% Therapeutic Approaches in Cancer Treatment
    Preț: 102417 lei
  • 5% Threshold Decision-making in Clinical Medicine: With Practical Application to Hematology and Oncology
    Preț: 70692 lei
  • 5% Epigenetics in Oncology
    Preț: 90465 lei
  • 5% Hodgkin’s Disease in Children: Controversies and Current Practice
    Preț: 47291 lei
  • 5% Molecular Genetics and Therapy of Leukemia
    Preț: 65184 lei
  • 5% Surgical Oncology
    Preț: 49135 lei
  • 5% Adrenal and Endocrine Tumors in Children: Adrenal Cortical Carcinoma and Multiple Endocrine Neoplasia
    Preț: 70905 lei
  • 5% Lung Cancer 1
    Preț: 36419 lei
  • 15% Bayesian Methods in Reliability
    Preț: 68831 lei
  • 5% Gynecologic Oncology
    Preț: 208105 lei
  • 5% Palliative Care and Rehabilitation of Cancer Patients
    Preț: 139020 lei
  • 5% Advances in Allogeneic Hematopoietic Stem Cell Transplantation
    Preț: 140011 lei
  • 5% HIV & HTLV-I Associated Malignancies
    Preț: 108802 lei
  • 5% Thoracic Oncology
    Preț: 127571 lei
  • 5% Cancer Chemoprevention
    Preț: 108462 lei
  • 5% Myelodysplastic Syndromes & Secondary Acute Myelogenous Leukemia: Directions for the New Millennium
    Preț: 107598 lei
  • 5% Liver-Directed Therapy for Primary and Metastatic Liver Tumors
    Preț: 107796 lei
  • 5% Biology and Management of Lung Cancer
    Preț: 138970 lei
  • 5% Non-Myeloablative Allogeneic Transplantation
    Preț: 70797 lei
  • 5% Atlas of Selective Sentinel Lymphadenectomy for Melanoma, Breast Cancer and Colon Cancer
    Preț: 69487 lei
  • 5% Clinically Relevant Resistance in Cancer Chemotherapy
    Preț: 71876 lei
  • 5% Biostatistical Applications in Cancer Research
    Preț: 139092 lei
  • 5% Head and Neck Cancer
    Preț: 109001 lei
  • 5% Signal Transduction in Cancer
    Preț: 107960 lei
  • 5% Kidney Cancer
    Preț: 107380 lei
  • 5% Angiogenesis in Brain Tumors
    Preț: 108102 lei
  • 5% The Biology of Skeletal Metastases
    Preț: 108766 lei

Preț: 90196 lei

Preț vechi: 94943 lei
-5% Nou

Puncte Express: 1353
Preț estimativ în valută:
17261€ • 17983$ • 14352£

Carte disponibilă

Livrare economică 21 ianuarie-04 februarie 25

 Adaugă în coș

Wish list
Gift list
Am citit!
Adaugă în listă
Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9783031300646
ISBN-10: 3031300645
Pagini: 328
Ilustrații: X, 328 p. 30 illus., 27 illus. in color.
Dimensiuni: 155 x 235 mm
Greutate: 0.73 kg
Ediția:1st ed. 2023
Editura: Springer International Publishing
Colecția Springer
Seria Cancer Treatment and Research

Locul publicării:Cham, Switzerland

Cuprins

Evolution of the development of PARP inhibitors.- Exploiting cancer synthetic lethality in cancer – Lessons learnt from PARP inhibitors.- Mechanisms of PARP inhibitor resistance.- Development of homologous recombination functional assays for targeting the DDR.- Clinical application of Poly(ADP Ribose) Polymerase (PARP) inhibitors in ovarian cancer.- Clinical use of PARP inhibitors in BRCA mutant and non-BRCA mutant breast cancer.- Development of PARP inhibitors in targeting castration-resistant prostate cancer.- Strategies for the management of patients with pancreatic cancer with PARP inhibitors.- Combining poly (ADP-ribose) polymerase (PARP) inhibitors with chemotherapeutic agents: Promise and challenges.- Rational combinations of PARP inhibitors with HRD-inducing molecularly targeted agents.- Combining PARP inhibition and immunotherapy in BRCA-associated cancers.- Mitotic MTH1 inhibitors in treatment of cancer.- Targeting ATR in cancer medicine.- Targeting polymerase Theta (POLq) for cancer therapy.- Targeting DNA-PK.- WRN is a promising synthetic lethal target for cancers with microsatellite instability (MSI).

Notă biografică

Dr. Timothy A. Yap is a Medical Oncology Physician-Scientist and tenured Professor based at the University of Texas MD Anderson Cancer Center. He is a Professor in the Department for Investigational Cancer Therapeutics (Phase I Program), and the Department of Thoracic/Head and Neck Medical Oncology. 

Dr. Yap is Vice President and Head of Clinical Development in the Therapeutics Discovery Division, a drug discovery biopharmaceutical division where drug discovery and clinical translation are seamlessly integrated. 

He is also the Associate Director of Translational Research in the Institute for Personalized Cancer Therapy, which is an integrated research and clinical trials program aimed at implementing personalized cancer therapy and improving patient outcomes. 

Dr. Yap’s main research focuses on the first-in-human and combinatorial development of molecularly targeted agents and immunotherapies, and their acceleration through clinical studies using novel predictive and pharmacodynamic biomarkers. His main interests include the targeting of the DNA damage response (DDR) with novel therapeutics through clinical trials and translational studies. These including targets such as ATR, PARP1, WEE1, POLQ, USP1, PARG, CHK1, ATM and DNA-PK inhibitors, next generation CDK4 and CDK2-selective inhibitors, WRN inhibitors, SMARCA2 inhibitors, YAP/TEAD inhibitors, as well as the development of novel immunotherapeutics.

Prior to his current position, Dr. Yap was a Consultant Medical Oncologist at The Royal Marsden Hospital in London, UK and National Institute for Health Research BRC Clinician Scientist at The Institute of Cancer Research, London, UK.

Dr. Shapiro currently serves as Senior Vice President, Developmental Therapeutics, at the Dana-Farber Cancer Institute (DFCI). In this role, he co-leads the Developmental Therapeutics Program for theDana-Farber/Harvard Cancer Center (DF/HCC) as well as the Cancer Center’s activities in the NCI-Cancer Therapy Evaluation Program (NCI-CTEP) Experimental Therapeutics Clinical Trials Network (ETCTN). He additionally serves as the Clinical Director for the DFCI Center for DNA Damage and Repair, where he has developed multiple predictive and pharmacodynamic biomarkers for DNA repair inhibitor agents, including those targeting PARP, the ATR-CHK1-WEE1 axis, and polymerase theta. Dr. Shapiro practices within the DFCI Center for Cancer Therapeutic Innovation, where he develops and leads multiple early phase trials focused primarily on cell cycle and DNA repair inhibitor therapeutics and provides mentorship to early career investigators. He has made proof-of-mechanism studies a mission of his program and has worked closely with basic and translational scientists at his institution and elsewhere to establish robust preclinical rationale for many trials. He also leads a complimentary laboratory effort where he studies resistance to these agents and their interaction with the immune microenvironment to inform the development of rational combinations.

Textul de pe ultima copertă

This book discusses the latest developments in Poly (ADP-ribose) polymerase (PARP) inhibitor drug development. It focuses on the translational and clinical development of the latest drugs, as well as the evidence for regulatory approval of PARP inhibitors in multiple different molecular subtypes and tumor indications. The most-up-to-date information on basic scientific research on DNA repair pathways and the DNA Damage Response (DDR) is also covered. Every chapter contains insight into the preclinical, translational along with clinical aspects of a specific DDR inhibitor with key and expert opinion points reinforcing the most important concepts detailed to enable the reader to develop a deep understanding of the topic.
 Targeting the DNA Damage Response for Cancer Therapy comprehensively reviews the application of PARP and other DDR inhibitors across oncology disciplines. Therefore, it is a valuable resource for all medical professionals and researchers who use or who are researching the use of these inhibitors on a day-to-day basis.

Caracteristici

Features detailed information on the latest translational studies on PARP inhibitors Contains 'key points' and 'expert opinion points' sections in each chapter for greater emphasis Provides detailed insight into preclinical/clinical development of rational combination studies for PARP inhibitors